Northpond Ventures LLC

Plus: Daniel Janse named CEO at AffyImmune, and updates from HanAll, Mogrify, Rectify and Atsena

Immunology company’s lead program targets a specific fibroblast subpopulation to induce formation of tertiary lymphoid structures in solid tumors

11 VCs have dominated the top 5 chart over the past five years, with RA Capital again leading this year

U.K. start-up raises near-$100M series B to push first-in-class pipeline into the clinic

By using enzyme-cleavable linkers instead of blocking groups, Ansa can generate long, undamaged DNA molecules

Plus: Culture, Anticancer, Rejuvenate, Regeneron and more

Approval for AbbVie’s migraine therapy, Sanofi’s mRNA plans, venture money for Expansion, Kytopen raise 

Amathus Therapeutics entered a strategic collaboration with Merck & Co. Inc. (NYSE:MRK) to develop small molecules for neurodegenerative diseases. Under the deal, Amathus will identify and conduct

Emerging Company Profile: After debuting with $50M, Atlas’ Vigil plans to pursue rare microgliopathies with assets from Amgen